C-C1-02: Validity of HMO Administrative Data for Breast Cancer Chemotherapy Exposure

  • Clinical Medicine & Research
  • November 2011,
  • 9
  • (3-4)
  • 146;
  • DOI: https://doi.org/10.3121/cmr.2011.1020.c-c1-02

Article Information

vol. 9 no. 3-4 146
DOI
https://doi.org/10.3121/cmr.2011.1020.c-c1-02
Published By
Clinical Medicine & Research
Print ISSN
1539-4182
History 
  • Published online November 15, 2011.
Copyright & Usage 
© 2011 Marshfield Clinic

Author Information

  1. Thomas Delate, PhD1,
  2. Erin Bowles, MPH2,
  3. Roy Pardee, JD2,
  4. Robert Wellman, MS2,
  5. Laurel Habel, PhD3,
  6. Marianne Yood, DSC4,
  7. Larissa Nekhlyudov, MD5,
  8. Katrina Goddard, PhD6,
  9. Robert Davis, MD7,
  10. Catherine Mccarty, PhD8,
  11. Adedayo Onitilo, MD8,
  12. Heather Feigelson, PhD1,
  13. Jared Freml, PharmD1 and
  14. Edward Wagner, MD2
  1. 1Kaiser Permanente Colorado
  2. 2Group Health Research Institute
  3. 3Kaiser Permanente Northern California
  4. 4Henry Ford Health System
  5. 5Harvard Pilgrim Healthcare Institute
  6. 6Kaiser Permanente Northwest
  7. 7Kaiser Permanente Georgia
  8. 8Marshfield Clinic
PDF
Back to top

In this Issue

Clinical Medicine & Research

Clinical Medicine & Research

Vol. 9, Issue 3-4

1 Nov 2011

Table of Contents Cover (Photo) Index by author

Jump to

Keywords

Chemotherapy, Sensitivity, Breast cancer